Pulmonary pseudoaneurysm in the setting of concurrent COVID‐19 and pulmonary mucormycosis: A rare case report

KEY CLINICAL MESSAGE: This case illustrates the possible danger of PAP emergence in individuals with a confluence of conditions capable of inducing vascular impairment, like COVID‐19, pulmonary mucormycosis (PM), and diabetes. ABSTRACT: Pulmonary mucormycosis (PM) is a highly lethal invasive infection. It is a rare complication of COVID‐19 and is associated with a high mortality rate. Pulmonary pseudoaneurysm (PAP) is a severe manifestation of this condition, often resulting in death. Management involves endovascular therapy followed by surgery and appropriate antifungal treatment.